- Dianthus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call TranscriptMay 03, 2023
- Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call TranscriptDec 13, 2022
- Magenta Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2022
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call TranscriptMay 12, 2021
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Magenta Therapeutics, Inc. - Special Call TranscriptMay 07, 2020
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Magenta Therapeutics Inc ASH 2019 TranscriptDec 08, 2019
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Okay. Great. I think we're going to get started here. I'm Terence Flynn, one of the biotech analysts at Goldman. And we're very pleased to have Magenta Therapeutics with us this afternoon. Joining us from the company is Jason Gardner, President and CEO.
Jason, thanks so much for being here with us this afternoon. Maybe just to start, given how new of a company you guys are, would just love a brief overview to kind of the formation of the company, the strategy and then why transplant. Like, why did you guys elect to focus there because it is somewhat novel in terms of the approach, and also taking this portfolio approach is somewhat different as well.
Well, first of all, Terence, thank you. Thank you for having me here and representing Magenta. It's a great pleasure. So we'll start at the end of that question, so why did we build Magenta, why transplant, why itâs this unique? So what we know is that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)